Enochian BioSciences is a pre-clinical stage biotechnology company. Co.'s product candidates include: ENOB-HV-01 for autologous Human Immunodeficiency Virus (HIV) curative treatment; ENOB-HV-11 for preventive HIV vaccine; ENOB-HV-12 for therapeutic HIV vaccine; ENOB-HV-21 for HIV natural killer and gamma delta T-cell treatment or cure; ENOB-HV-31 for in vivo gene therapy; ENOB-HB-01 for hijacking Hepatitis B Virus polymerase; ENOB-CV-01 for coronavirus treatment; ENOB-CV-11 for coronavirus prophylaxis; ENOB-FL-01 for influenza treatment; ENOB-FL-11 for influenza prophylaxis; and ENOB-DC-11 for off the shelf dendritic cell vaccine for multiple solid tumors. The ENOB average annual return since 2018 is shown above.
The Average Annual Return on the ENOB average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ENOB average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ENOB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|